BIOPHTA

BIOPHTA is a preclinical-stage biotechnology company developing a technology for the treatment of ophthalmic diseases. BIOPHTA's first project focuses on glaucoma treatment, and the second project targets macular edema. The company’s unique ophthalmic implant technology can address other conditions in both the anterior and posterior segments of the eye, such as allergic conjunctivitis, dry eye syndrome, post-cataract surgery, and age-related macular degeneration, thus covering a wide range of indications.